Rain Therapeutics Announces an Oral Presentation at the Connective Tissue Oncology Society Annual Meeting
NEWARK, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced an oral presentation at the Connective Tissue Oncology Society (CTOS) Annual Meeting taking place on November 16-19, 2022 in Vancouver, BC, Canada.
About Rain Therapeutics Inc.
Medical Internet of Things (MIoT) - Opportunities for Managed Solutions Providers (MSPs)
Taking Your MSP Business To New Heights With CPaaS
What Do Web3 and Metaverse Mean for the Future of Business?